AYTU Nasdaq Pharmaceutical Preparations Financials FY2017βFY2026
Aytu Biopharma, Inc had $57.6M of revenue in fiscal 2026, down 13.3% on the year before. Over five years, revenue changed β2.6% a year on average.
Last close Β· Oct 23, 2026
$1.90
4.0%Hi! I read Aytu Biopharma, Incβs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β13.3%
No. Sales fell 13.3% last year.
Does it make a profit?
β24.8%
No. It lost money last year.
Does profit turn into cash?
5.6%
Partly. 5.6% of sales ends up as free cash.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Aytu Biopharma, Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Sep 22, 2026 | Q4 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q3 '26 | After the market closes | 8-K β |
| Feb 3, 2026 | Q2 '26 | After the market closes | 8-K β |
| Nov 13, 2025 | Q1 '26 | After the market closes | 8-K β |
| Sep 23, 2025 | Q4 '25 | After the market closes | 8-K β |
| May 14, 2025 | Q3 '25 | After the market closes | 8-K β |
| Feb 12, 2025 | Q2 '25 | After the market closes | 8-K β |
| Nov 11, 2024 | Q1 '25 | Time not announced | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Aytu Biopharma, Inc had $57.6M of revenue in fiscal 2026, down 13.3% on the year before. Over five years, revenue changed β2.6% a year on average. Its operating margin was β14.4%, down 2.7Β pts: of every 100 in sales, about β14 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Aytu Biopharma, Inc lost $14.3M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $3.3M in fiscal 2026, 5.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Aytu Biopharma, Inc has $15.4M more cash than debt.
Cash, debt and the ratios that show how comfortably Aytu Biopharma, Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $19.4M | $23.0M | $20.0M | $31.0M | $26.3M |
| Debt incl. finance leases | $19.0M | $16.6M | $15.1M | $12.8M | $11.0M |
| Net debt / EBITDA | β | β | β0.7x | β | β |
| Debt / equity | 0.4x | 0.4x | 0.5x | 0.7x | 0.3x |
| Interest coverage | β122.1x | β3.4x | β0.3x | β2.1x | β4.4x |
| Current ratio | 0.9x | 1.1x | 1.0x | 1.3x | 1.1x |
| Quick ratio | 0.8x | 0.9x | 0.8x | 1.1x | 1.0x |
| Total assets | $138M | $136M | $118M | $124M | $105M |
| Total liabilities | $93.3M | $97.1M | $90.4M | $105M | $69.7M |
| Shareholders' equity | $44.3M | $39.4M | $27.7M | $19.0M | $35.3M |
| Net debt (β = net cash) | β$0.4M | β$6.3M | β$4.9M | β$18.2M | β$15.4M |
KIRA Β· Its return on capital was β33.0%: every 100 invested in the business earned about β33 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Aytu Biopharma, Inc passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 4 / 9 | 3 / 9 | 2 / 9 | 4 / 9 | 6 / 9 | 2 / 8 | 4 / 8 | 3 / 8 |
| Accruals ratio | β57.9% | 31.9% | β47.7% | 15.7% | β15.4% | β39.7% | β8.7% | β11.4% | β9.6% | β15.3% |
| Altman Z'' | β23.90 | β14.82 | β11.08 | 0.23 | β2.65 | β11.88 | β7.50 | β8.62 | β8.14 | β10.35 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.2M | $3.7M | $7.3M | $27.6M | $65.6M | $96.7M | $107M | $65.2M | $66.4M | $57.6M |
| Gross profit | $1.8M | $1.6M | $5.1M | $19.4M | $29.2M | $52.3M | $66.6M | $49.1M | $45.8M | $36.8M |
| Research and development | $1.0M | $0.2M | $0.6M | $1.7M | $5.6M | $12.7M | $4.1M | $2.8M | $1.3M | $0.0M |
| Operating income | β$20.1M | β$19.7M | β$16.8M | β$21.1M | β$58.9M | β$110M | β$17.1M | β$1.6M | β$7.8M | β$8.3M |
| Interest expense | $2.5M | $0.7M | $0.5M | $2.6M | β | $0.9M | $5.0M | $5.1M | $3.7M | $1.9M |
| Pretax income | β | β | β | β$13.6M | β$58.0M | β$109M | β$17.1M | β$10.4M | β$13.7M | β$14.2M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.3M | β$0.1M | $0.0M | $2.1M | $0.4M | $0.0M |
| Net income | β$22.5M | β$10.2M | β$27.1M | β$13.6M | β$58.3M | β$109M | β$17.1M | β$15.8M | β$13.6M | β$14.3M |
| Diluted EPS | β$48.30 | β$15.31 | β$3.48 | β$3.01 | β$3.48 | β$74.01 | β$5.11 | β | β | β |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.00B | 0.02B | 0.00B | 0.00B | β | β | β |
| Cash flow | ||||||||||
| Cash from operations | β$13.8M | β$15.9M | β$13.8M | β$28.4M | β$26.0M | β$28.8M | β$5.1M | β$1.4M | β$1.9M | $3.3M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.0M | $2.3M | $0.0M | β | $0.3M | $0.2M | $0.0M |
| Free cash flow | β$13.9M | β$16.0M | β$13.9M | β$28.4M | β$28.3M | β$28.8M | β | β$1.7M | β$2.2M | $3.3M |
| Depreciation and amortization | $4.4M | $2.6M | $2.7M | $5.7M | $9.2M | $10.1M | $8.8M | $8.3M | $5.4M | $3.9M |
| Stock-based compensation | $2.5M | $0.6M | $1.0M | $1.1M | $3.6M | $5.2M | $6.0M | $2.4M | $0.6M | $0.7M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.8M | $7.0M | $11.0M | $48.1M | $49.6M | $19.4M | $23.0M | $20.0M | $31.0M | $26.3M |
| Total debt | β | $0.0M | $0.0M | $2.0M | $16.8M | $18.8M | $16.6M | $15.1M | $12.8M | $11.0M |
| Finance lease liabilities | β | β | β | β | $0.3M | $0.2M | $0.1M | $0.0M | $0.0M | $0.0M |
| Current assets | $3.0M | $9.5M | $15.4M | $75.4M | $105M | $59.9M | $72.8M | $61.9M | $79.2M | $61.8M |
| Current liabilities | $3.6M | $3.4M | $5.4M | $28.8M | $109M | $64.4M | $69.0M | $62.2M | $63.1M | $54.7M |
| Inventory | $1.3M | $1.3M | $1.4M | $10.0M | $16.3M | $10.8M | $12.0M | $12.1M | $11.4M | $6.9M |
| Property and equipment, net | $0.6M | $0.2M | $0.2M | $0.3M | β | β | $1.8M | $0.7M | $0.5M | $0.4M |
| Goodwill | $0.2M | β | $0.0M | $28.1M | $65.8M | $0.0M | $0.0M | β | β | β |
| Intangible assets | $0.3M | $0.2M | $48.9M | $48.9M | $85.5M | $70.6M | $59.0M | $52.5M | $42.2M | $41.4M |
| Total assets | $15.0M | $21.1M | $34.7M | $153M | $266M | $138M | $136M | $118M | $124M | $105M |
| Total liabilities | $11.0M | $7.6M | $27.6M | $58.3M | $128M | $93.3M | $97.1M | $90.4M | $105M | $69.7M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $4.0M | $13.4M | $7.1M | $95.0M | $138M | $44.3M | $39.4M | $27.7M | $19.0M | $35.3M |
| Margins | ||||||||||
| Gross margin | 56.0% | 44.0% | 69.9% | 70.0% | 44.5% | 54.1% | 62.0% | 75.3% | 69.0% | 64.0% |
| Operating margin | β624.7% | β538.2% | β230.1% | β76.5% | β89.7% | β113.7% | β15.9% | β2.4% | β11.8% | β14.4% |
| EBITDA margin | β489.2% | β467.4% | β192.9% | β55.8% | β75.7% | β103.2% | β7.7% | 10.2% | β3.7% | β7.6% |
| Net margin | β698.7% | β278.4% | β370.6% | β49.3% | β88.8% | β112.5% | β15.9% | β24.3% | β20.4% | β24.8% |
| FCF margin | β432.7% | β437.6% | β189.8% | β102.7% | β43.1% | β29.8% | β | β2.6% | β3.3% | 5.6% |
| Returns | ||||||||||
| Return on capital | β | β242.7% | β | β34.1% | β44.4% | β198.4% | β40.9% | β5.5% | β807.2% | β33.0% |
| Return on capital employed | β176.7% | β111.5% | β57.4% | β17.0% | β37.7% | β150.2% | β25.3% | β2.8% | β12.8% | β16.5% |
| Return on equity | β562.7% | β116.9% | β264.5% | β26.7% | β50.1% | β119.6% | β40.8% | β47.2% | β58.1% | β52.6% |
| Return on assets | β150.1% | β56.5% | β97.3% | β14.5% | β27.8% | β53.9% | β12.4% | β12.4% | β11.2% | β12.4% |
| Return on tangible equity | β644.9% | β77.3% | β | β75.4% | β | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | 13.6% | 100.0% | 277.5% | 137.5% | 47.3% | 11.1% | β39.3% | 1.8% | β13.3% |
| Share count change | β | 42.8% | 1,071.0% | β42.0% | 270.6% | β91.2% | 127.2% | β | β | β |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β0.7x | β | β |
| Debt / equity | β | 0.0x | 0.0x | 0.0x | 0.1x | 0.4x | 0.4x | 0.5x | 0.7x | 0.3x |
| Interest coverage | β7.9x | β26.3x | β31.5x | β8.1x | β | β122.1x | β3.4x | β0.3x | β2.1x | β4.4x |
| Current ratio | 0.8x | 2.8x | 2.9x | 2.6x | 1.0x | 0.9x | 1.1x | 1.0x | 1.3x | 1.1x |
| Quick ratio | 0.5x | 2.4x | 2.6x | 2.3x | 0.8x | 0.8x | 0.9x | 0.8x | 1.1x | 1.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.5% | 2.0% | 0.8% | 0.0% | 3.6% | 0.0% | β | 0.5% | 0.3% | 0.1% |
| Stock comp / revenue | 77.7% | 16.3% | 14.0% | 3.9% | 5.4% | 5.4% | 5.6% | 3.6% | 0.9% | 1.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 4.0 | 3.0 | 2.0 | 4.0 | 6.0 | 2.0 | 4.0 | 3.0 |
| Altman Z'' | β23.9 | β14.8 | β11.1 | 0.2 | β2.7 | β11.9 | β7.5 | β8.6 | β8.1 | β10.4 |
| Accruals ratio | β57.9% | 31.9% | β47.7% | 15.7% | β15.4% | β39.7% | β8.7% | β11.4% | β9.6% | β15.3% |
Source: SEC EDGAR XBRL filings (CIK 0001385818). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
